内科学
内分泌学
蛋白激酶B
非酒精性脂肪肝
医学
PI3K/AKT/mTOR通路
甘油三酯
血脂
IRS1
脂肪肝
胰岛素抵抗
2型糖尿病
糖尿病
碳水化合物代谢
脂质代谢
胰岛素受体
胰岛素
胆固醇
信号转导
生物
生物化学
疾病
作者
Yanbo Fan,Zhiwei He,Wei Wang,Jingjing Li,Aimin Hu,Li Li,Ling Yan,Zhijie Li,Qiang Yin
标识
DOI:10.1016/j.biopha.2018.06.089
摘要
Previous clinical studies have demonstrated that tangganjian (TGJ), a modern Chinese prescribed medicine, has a clinical effect in the treatment of type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Our study aimed to investigate whether the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is involved in this therapeutic effect.T2DM and NAFLD rat models were constructed and treated with three different concentrations of TGJ. Pioglitazone was used as a positive control, along with the model and normal groups. For analyses, blood and livers were collected. Levels of glucose and lipid metabolism indicators, including fasting insulin and total cholesterol, were determined. The expression levels of insulin receptor substrate (IRS), PI3K, and AKT were also determined by western blotting and immunohistochemistry. Liver tissues were stained with hematoxylin & eosin.In the high-dose TGJ-treated and positive groups, there was a significant increase in the HDL-C level and decreases in the levels of the fasting blood glucose, 2 h postprandial blood glucose, fasting insulin, triglyceride, total cholesterol, and low-density lipoprotein cholesterol, along with a significant increase in the expression of IRS, PI3K, and AKT in the liver. TGJ could also attenuate or counteract the effects of T2DM and NAFLD in the liver lobules.A high concentration of TGJ can improve glucose and lipid metabolism by activating the IRS/PI3K/AKT signaling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI